PETALING JAYA: TMC Life Sciences Bhd is targeting its fertility business to contribute 30% to the group’s revenue from the current 17% for the financial year ending June 2021 (FY21).
This revenue contribution growth will be partly driven by the group’s fertility centre in Puchong, which is expected to begin operations this May.
Speaking after TMC’s annual general meeting on Thursday, group CEO Wan Nadiah Wan Mohd Abdullah Yaakob said, “While the hospital business continues to be the group’s mainstream business, our fertility business is showing double-digit growth in revenue.
“Going forward, we expect the fertility business to grow faster than before.”
On Covid-19 effect on the group’s fertility business, Nadiah noted that there has been deferments and cancellations from its patients from China.
However, this is offset by local fertility patients and those from Indonesia.
Did you find this article insightful?